Tanshinone IIA Ameliorates Inflammation Response in Osteoarthritis via Inhibition of miR-155/FOXO3 Axis

Background: Osteoarthritis (OA) is the most common joint disorder characterized by degeneration of the articular cartilage and joint destruction with an associated risk of mobility disability in elderly people. Although a lot of achievements have been made, OA is still regarded as an incurable disease. Therefore, the pathological mechanisms and novel therapeutic strategies of OA need more investigation. Methods: MTT assay was conducted to measure the viability of chondrocytes after LPS treatment. Cell apoptosis was analyzed by annexin V/propidium iodide labeling. ELISA was used to determine the concentrations of interleukin (IL)-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha in the culture supernatant of chondrocytes. The expression level of miR-155, IL-1 beta, FOXO3, TNF-alpha, IL-6, caspase-3, and caspase-9 in chondrocytes was analyzed by RT-qPCR or Western blot. Results: We found that LPS led to inflammatory responses, cell apoptosis, and increased miR-155 expression in human articular chondrocytes. Tanshinone IIA could inhibit LPS-induced inflammation and cell apoptosis of chondrocytes via regulating the expression of miR-155 and FOXO3. miR-155 directly targeted the 3 '-UTR of FOXO3 to regulate its expression. Conclusions: Taken together, our data suggest tanshinone IIA ameliorates inflammation response in OA via inhibition of the miR-155/FOXO3 axis, and provide some evidences that tanshinone IIA could be designed and developed as a new promising clinical therapeutic drug for OA patients. (c) 2021 S. Karger AG, Basel

Automated summary

The study showed that LPS induced inflammatory responses and cell apoptosis in human articular chondrocytes, while tanshinone IIA could inhibit these effects by regulating miR-155 and FOXO3. The findings suggest tanshinone IIA may ameliorate inflammation in OA and have potential as a new therapeutic drug for OA patients.